DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+9.27%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$423M
AUM Growth
+$423M
(+1.1%)
Cap. Flow
-$19.4M
Cap. Flow
% of AUM
-4.58%
Top 10 Holdings %
Top 10 Hldgs %
48.91%
Holding
89
New
6
Increased
19
Reduced
26
Closed
5
Top Buys
| 1 |
Lexeo Therapeutics
LXEO
|
$2.27M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$1.57M |
| 3 |
IDEAYA Biosciences
IDYA
|
$1.56M |
| 4 |
Ascendis Pharma
ASND
|
$1.28M |
| 5 |
Structure Therapeutics
GPCR
|
$1.27M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$7.9M |
| 2 |
SPDR S&P Biotech ETF
XBI
|
$4.3M |
| 3 |
Viking Therapeutics
VKTX
|
$4.02M |
| 4 |
Syndax Pharmaceuticals
SNDX
|
$2.51M |
| 5 |
TSVT
2seventy bio
TSVT
|
$1.99M |
Sector Composition
| 1 | Healthcare | 86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
ProQR Therapeutics
PRQR
$247M
| $1.65M | 0.39% |
905,582
| – | – |
|
|
CMPS
52
Compass Pathways
CMPS
$445M
| $1.53M | 0.36% |
243,210
| – | – |
|
|
53
Structure Therapeutics
GPCR
$1.19B
| $1.49M | 0.35% |
34,000
+29,000
| +580% | +$1.27M |
|
54
Immunovant
IMVT
$2.68B
| $1.48M | 0.35% |
51,996
+4,080
| +9% | +$116K |
|
|
RGLS
55
DELISTED
Regulus Therapeutics
RGLS
| $1.41M | 0.33% |
895,200
| – | – |
|
56
Gossamer Bio
GOSS
$587M
| $1.4M | 0.33% |
1,419,262
+10,000
| +0.7% | +$9.86K |
|
57
Lineage Cell Therapeutics
LCTX
$279M
| $1.22M | 0.29% |
1,350,708
| – | – |
|
58
MediWound
MDWD
$179M
| $1.16M | 0.28% |
64,479
-60,000
| -48% | -$1.08M |
|
59
Sutro Biopharma
STRO
$82.8M
| $1.14M | 0.27% |
329,579
| – | – |
|
60
PolyPid
PYPD
$54.7M
| $1.06M | 0.25% |
308,497
+123,651
| +67% | +$425K |
|
|
NYXH
61
Nyxoah
NYXH
$230M
| $1.03M | 0.24% |
108,108
| – | – |
|
62
BioNTech
BNTX
$24.1B
| $1.01M | 0.24% |
+8,500
| New | +$1.01M |
|
63
Adicet Bio
ACET
$60.9M
| $864K | 0.2% |
600,000
| – | – |
|
64
Compugen
CGEN
$134M
| $809K | 0.19% |
447,202
-15,000
| -3% | -$27.2K |
|
65
Acrivon Therapeutics
ACRV
$43.1M
| $787K | 0.19% |
112,414
-8,937
| -7% | -$62.6K |
|
|
SAGE
66
DELISTED
Sage Therapeutics
SAGE
| $781K | 0.18% |
108,200
-8,000
| -7% | -$57.8K |
|
|
GRAL
67
GRAIL, Inc. Common Stock
GRAL
$1.15B
| $671K | 0.16% |
+48,800
| New | +$671K |
|
68
ADC Therapeutics
ADCT
$355M
| $643K | 0.15% |
204,081
| – | – |
|
69
Black Diamond Therapeutics
BDTX
$159M
| $544K | 0.13% |
+125,000
| New | +$544K |
|
70
Tourmaline Bio
TRML
$619M
| $491K | 0.12% |
19,110
-56,872
| -75% | -$1.46M |
|
71
BiomX
PHGE
$14.3M
| $409K | 0.1% |
+401,136
| New | +$409K |
|
72
Masimo
MASI
$7.4B
| $400K | 0.09% |
3,000
| – | – |
|
73
Verastem
VSTM
$575M
| $382K | 0.09% |
+127,700
| New | +$382K |
|
74
Aprea Therapeutics
APRE
$9.03M
| $377K | 0.09% |
137,174
| – | – |
|
75
Foghorn Therapeutics
FHTX
$303M
| $351K | 0.08% |
37,664
-4,186
| -10% | -$39K |
|